| Document |
Document Title |
|
WO/2024/074628A1 |
The present invention relates to a compound of Formula (I) and a composition containing, a process of producing the compound and a method of using of the compound and the compositions to prevent or control fungi in plants.
|
|
WO/2023/192233A1 |
Described are compositions and methods for treating pain and/or increasing opioid therapy efficacy and ameliorating opioid use disorder. The compositions and methods target Gαq/11 signaling.
|
|
WO/2023/138644A1 |
Provided is a new polypeptide. The new polypeptide shows a significant effect of relieving intestinal lumen distension in pharmacodynamic tests of a Brachydanio Rerio inflammatory bowel disease model and a rat inflammatory bowel disease ...
|
|
WO/2023/093596A1 |
The present invention relates to a novel cyclic polypeptide carrier and variants thereof in the technical field of medicines, wherein the cyclic polypeptide has a sequence general formula P-(X)m-Cys-(Y)n-Cys-(Z)o-P. The present invention...
|
|
WO/2023/077447A1 |
Disclosed are a cyclopeptide glass and a pharmaceutical composition glass containing a cyclopeptide. The cyclopeptide glass of the present invention can simultaneously exert efficacy and a drug adjuvant function. Compared with crystals a...
|
|
WO/2023/001350A1 |
Here we introduce a modified peptide J1d (from jellein1 peptide in MRJP1) as we changed 2 amino acids to D form in N terminus and C terminus of jellein 1 peptide and added NH2 group to its N terminus and COOH group to C terminus. Another...
|
|
WO/2023/274145A1 |
A method for preparing a dehydrodidemnin B compound. The method comprises: subjecting a Didemnin B compound, as represented by formula Ⅰ, and an oxidizing agent to an oxidation reaction in an organic solvent to prepare the dehydrodidem...
|
|
WO/2022/271936A1 |
The present invention directed to a novel macrocyclic depsipeptide compound, its derivatives, and their pharmaceutically acceptable salts, having selective antibacterial activity against M. tuberculosis.
|
|
WO/2022/215495A1 |
The present invention addresses the problem of providing a means for reducing the bioburden of a cyclic lipopeptide compound product through a simple operation without loss of quality or function thereof. The present invention pertains...
|
|
WO/2022/162332A1 |
A compound of formula (I) or formula (II) including tautomeric or stereochemically isomeric forms thereof, wherein: R1 represents C1-20 alkyl, C2-20 alkenyl, C6-20 aryl, or C4-20 heterocyclyl, each optionally substituted with one or more...
|
|
WO/2022/094273A1 |
In one aspect, the invention relates to cyclopeptides and methods of using the disclosed cyclopeptides to treat bacterial infections due to, for example, Gram-negative pathogens. This abstract is intended as a scanning tool for purposes ...
|
|
WO/2022/019657A1 |
The present invention relates to a novel cyclic pentadepsipeptide, a novel microorganism producing same, and a composition comprising the compound as an active ingredient for regeneration or would healing. More specifically, the present ...
|
|
WO/2021/198999A1 |
The disclosures described herein relate to polypeptides, antibodies, and compositions for use in the treatment and diagnosis of severe acute respiratory syndrome (SARS) coronavirus-associated diseases or disorders. Provided are new immun...
|
|
WO/2021/161292A1 |
A composition for targeting low-density lipoprotein receptor-related protein 6 (LRP6)-overexpressed cells. The composition includes a peptide including at least one of SEQ ID NO: 1 and SEQ ID NO: 3. The composition may further include a ...
|
|
WO/2021/087037A1 |
Disclosed is a synthetic, non-naturally occurring 12-amino acid peptide, Lung-specific Targeting Peptide, belonging to the larger class of cell penetrating peptides, for delivery of both diagnostic and potentially therapeutic agents to t...
|
|
WO/2021/011283A1 |
Described herein are isolated peptides, compositions comprising the same, and methods of using such peptides or compositions in the treatment of depression, central nervous system disorders, and neurodevelopmental disorders.
|
|
WO/2020/264389A1 |
Novel peptide analogs of a θ-defensin have been developed that provide a biphasic effect in treating infection and/or sepsis. These analogs are active at concentrations below those needed to provide a bactericidal or bacteriostatic effe...
|
|
WO/2020/264328A1 |
Novel peptide analogs of a θ-defensin have been developed that provide a biphasic effect in treating disseminated fungal disease and/or associated septic shock. These analogs are active at concentrations below those needed to provide a ...
|
|
WO/2020/232048A1 |
Provided herein are thiostrepton analogues, such as but not limited to compounds of Formula I, with improved aqueous solubility and antibacterial properties against antibiotic-resistant bacterial strains. The methods of the invention fur...
|
|
WO/2020/173926A1 |
The invention relates to the use of a destruxin or derivatives thereof for preventing or combating Clostridium perfringens in human or veterinary therapy or in animal nutrition.
|
|
WO/2020/152043A1 |
The invention relates to an organic molecule, in particular for the application in optoelectronic devices. According to the invention, the organic molecule has a structure of formula (I) R1 and R2 are independently selected from the grou...
|
|
WO/2020/149258A1 |
Provided is a new immune checkpoint inhibitor. The present invention provides an immune checkpoint inhibitor having as an active ingredient one or more selected from a peptide fragment of the N-end region of caveolin 1, a peptide fragmen...
|
|
WO/2020/144166A1 |
The present invention relates to new peptides derived from HD-5 or HNP-4 having antimicrobial activity for use in modulating the microbiome of intestines, the lungs, the skin, the mouth, the eye, the ear, the vagina or other bodily surfa...
|
|
WO/2020/122182A1 |
The present inventor found that the membrane permeability of a peptide compound can be improved by employing at least one amino acid which has a side chain capable of forming an intermolecular hydrogen bond, as one of the amino acids con...
|
|
WO/2020/117429A1 |
The present disclosure relates to novel antibacterial cell-penetrating peptides and derivatives, and methods to make and use the novel antibacterial cell-penetrating peptides and derivatives. The novel antibacterial cell-penetrating pept...
|
|
WO/2019/227240A1 |
Methods and uses for treating cancer in a subject are provided. In particular, the present disclosure provides methods and uses relating to treating a subject with cancer by activating human mitochondrial ClpP (HsClpP). The present discl...
|
|
WO/2019/217116A1 |
The present disclosure relates in general to the field of peptide synthesis. In general, the system provides for solution-phase peptide synthesis methods in organic solvents, some of which are immiscible with aqueous solutions, alkane so...
|
|
WO/2019/191527A1 |
rovided herein are compounds that inhibit protein secretion, e.g., via inhibition of Sec61. Also provided are compositions of the inhibitor compounds, and methods of using these inhibitors. The compounds disclosed herein can be used, e.g...
|
|
WO/2019/157293A1 |
Disclosed herein are apratoxin analogs.
|
|
WO/2019/151439A1 |
The purpose of the present invention is to provide an echinomycin derivative having anti-cancer activity equal to or greater than that of echinomycin, and a production method therefor based on a chemical procedure. Provided are an echino...
|
|
WO/2019/119302A1 |
Disclosed in the present invention are CMKLR1 antagonist polypeptides (SEQ ID No: 1-17) and derivatives and applications thereof. The derivatives of the polypeptides are products obtained by conventional modification on amino acid side c...
|
|
WO/2019/119303A1 |
Disclosed in the present invention are a CMKLR1 antagonistic polypeptide (the sequences being SEQ ID No: 1-24), and a derivative and application thereof. The derivative of the polypeptide is a product obtained by conventionally modifying...
|
|
WO/2019/115765A1 |
The invention relates to a peptide siderophore, comprising one or more N-nitroso-hydroxylamine ligands. In a preferred embodiment, the peptide siderophore comprises two side chains, each with a N-nitroso-hydroxylamine ligand, and a furth...
|
|
WO/2019/108591A1 |
The present invention provides cyclic depsipeptides of Formula (1), stereoisomers thereof, and veterinary acceptable salts thereof (1) wherein each of R1, R2, R3, R4, L1, and L2, are as defined herein. The present invention also contempl...
|
|
WO/2019/091975A1 |
The present invention relates to a method for the synthesis of cyclic depsipeptides, in particular emodepside, from the open form.
|
|
WO/2019/040589A1 |
Provided is a method of producing a PF1022A derivative, said method comprising the steps of: reacting a compound of Formula II: wherein R1 and R2 are independently selected from hydrogen, halo and triflate, subject to the proviso that at...
|
|
WO/2019/040585A1 |
Provided herein are improved methods of producing a derivative of PF1022A, for example a compound of Formula I: Formula I wherein R1 and R2 are each independently hydrogen or nitro, and at least one of R1 and R2 is nitro. In some embodim...
|
|
WO/2019/013148A1 |
A liganded substrate having at least part of the surface thereof covered by a polymer (P1) containing a structural unit represented by formula (1a) and (1b), a raw material of said liganded substrate, and a production method thereof are ...
|
|
WO/2018/232152A1 |
Provided are methods for determining whether a glioblastoma (GBM) tumor or GBM cancer cell will be sensitive to a treatment targeting the integrin avb3 (alpha.v.beta.3.) pathway, comprising determining whether the GBM tumor or the GBM ca...
|
|
WO/2018/225851A1 |
A method for producing a peptide containing an N-substituted amino acid or an N-substituted amino acid analogue according to the present invention includes the steps of: preparing an Fmoc-protected amino acid, an Fmoc-protected amino aci...
|
|
WO/2018/214463A1 |
A compound represented by formula I or a stereoisomer, tautomer, oxynitride, hydrate, solvate, metabolite, or pharmaceutically acceptable salt or prodrug of the compound represented by formula I.
|
|
WO/2018/187173A1 |
The present invention relates generally to novel depsipeptides, to methods for the preparation of the novel depsipeptides, to pharmaceutical compositions comprising the novel depsipeptides; and to methods of using the novel depsipeptides...
|
|
WO/2018/166899A1 |
Provided are processes for the production of PF1022A derivative compounds, including incubating a microorganism strain capable of producing such compounds in a culture medium to produce a resulting culture, said culture medium containing...
|
|
WO/2018/151839A1 |
The present invention is directed to antimicrobial agents and compositions including the same. The antimicrobial agent can include a polypeptide or a peptidomimetic of the polypeptide. The polypeptide can have a net positive charge of at...
|
|
WO/2018/106545A1 |
This disclosure describes compositions and methods for enhanced production of enduracidin in genetically engineered strains of Streptomyces fungicidicus. In particular, the present disclosure describes the genetic manipulation of regulat...
|
|
WO/2018/103905A1 |
The present invention is drawn to modified Streptomyces fungicidicus isolates, to compositions comprising these isolates, and methods of using such isolates and compositions to biologically synthesize enduracidin (enramycin). In addition...
|
|
WO/2018/093920A1 |
The present invention provides cyclic depsipeptide compounds of formula (I) wherein the stereochemical configuration of at least one carbon atom bearing the groups Cy1, Cy2, R1, R2, R3, R4, Ra and Rb is inverted compared with the natural...
|
|
WO/2018/081898A1 |
CD47+ disease cells such as cancer cells are treated using a combination of CD47 blockade drug and a histone deacetylase (HDAC) inhibitor. The anti-cancer effect of one drug enhances the anti-cancer effect of the other. Specific combinat...
|
|
WO/2018/045313A1 |
In one aspect, the invention relates to substituted urea depsipeptide analogs, derivatives thereof, and related compounds, which are useful as activators the ClpP endopeptidease; synthesis methods for making the compounds; pharmaceutical...
|
|
WO/2018/045245A1 |
Provided are cyclic peptide analogs, conjugates comprising such compounds, and pharmaceutical compositions comprising such compounds and conjugates, and methods of treating cancer with such compounds and conjugates.
|
